Tips and tricks in triple-negative breast cancer: how to manage patients in real-life practice? by Piccart, M et al.
1
C
o
n
f
e
r
e
n
c
e
 
R
e
p
o
r
t
ecancermedicalscience
Tips and tricks in triple-negative breast cancer: how to manage  
patients in real-life practice?
M Piccart1,2, G Viale3,4, P Ellis5,6, M Abramowicz7,8 and L Carey9
1Free University of Brussels, Brussels, Belgium
2Department of Medicine, Jules Bordet Institute, Brussels, Belgium
3University of Milan School of Medicine, Milan, Italy
4Division of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy
5Guy’s Hospital, London, UK
6Cancer Medicine, King’s College, London, UK
7Department of Genetics, Centre of Human Genetics, Hôpital Erasme, Brussels, Belgium
8Human and Medical Genetics, Free University of Brussels, Belgium
9Department of Medicine, Division of Hematology/Oncology, University of North Carolina, Chapel Hill, North Carolina, USA
Correspondence to  Martine Piccart. Email: martine.piccart@bordet.be
Published: 19/07/2011  Received: 04/07/2011
ecancer 2011, 5:217 DOI: 10.3332/ecancer.2011.217
Copyright: © the authors; licensee ecancermedicalscience. This is an Open Access article distributed under the terms of the Creative 
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction 
in any medium, provided the original work is properly cited.ecancer 2011, 5:217
www.ecancermedicalscience.com 2
C
o
n
f
e
r
e
n
c
e
 
R
e
p
o
r
t
Introduction
This article has been developed following, and drawing on the content of, a satellite meeting at the fifth International Breast Cancer 
Conference, held in Paris, France, on 29 January 2011. The purpose of the meeting was to examine several questions relating to triple-
negative breast cancer (TNBC):
•  How should TNBC be defined?
•  Are there clinically important TNBC subtypes?
•  Should patients be given adjuvant or neoadjuvant treatment for TNBC?
•  Should patients with TNBC and their families have genetic tests?
•  How should relapsing or metastatic TNBC be treated?
Using a real-life case study, at each stage of the patient care pathway from diagnosis through assessment to treatment, the audience was 
encouraged to vote on potential decisions, before an expert panel on which we all sat discussed the evidence and presented what we 
consider constitutes best clinical practice.
In this article we share the proceedings of the meeting, which we believe contained valuable educational content of potential interest to 
the wider healthcare community.
Case study
Carole is a 37-year-old primary school teacher, with a husband and two young children (a 7-year-old daughter and a 3-year-old 
son). She presented, in January 2010, with a palpable large tumour mass (6 cm) in her right breast. She was diagnosed with a right 
mammary tumour (T4N2), with carcinomatous mastitis and four suspicious lymph nodes. Biopsy confirmed a grade 3 invasive duc-
tal carcinoma that was negative for oestrogen receptors (ER), progesterone receptors (PgR) and human epidermal growth factor 
receptor 2 (HER2).
How should TNBC be defined?
Audience voting
When offered potential definitions for ER or PgR negativity, most of the audience (58%) agreed on a cutoff of 1% positive cells, although 
around a third would use 10% as a cutoff. Most participants (89%) would use fluorescence in situ hybridization (FISH) to confirm HER2 
status if the immunohistochemistry (IHC) test was 2+; in some countries (such as Belgium), FISH testing is mandatory for trastuzumab 
reimbursement, regardless of IHC score.
Expert opinion of Professor Giuseppe Viale
Concordance on thresholds for defining ER and PgR negativity is vital to ensure that pathologists and clinicians describe and treat 
patients consistently. The joint American Society of Clinical Oncology (ASCO) and College of American Pathologists guidelines on IHC 
testing in breast cancer [1] have specified a cutoff of 1% immunoreactive cells.www.ecancermedicalscience.com 3
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There is a concern that patients with 1–10% immunoreactive cells are not responsive to endocrine therapy; however, review of patients 
recruited into clinical trials of tamoxifen and aromatase inhibitors has shown that these patients have a greater benefit from endocrine 
treatment than those who have less than 1% immunoreactive cells. The question should not be “Is it worth treating this patient?” but rather 
“Am I sure I can deny this patient the possible benefit of endocrine treatment?”
Pathologists need to confirm the lack of immunoreactive cells (negative ER status) in the tissue sample by a positive control in normal 
ducts to avoid any false negative reports and to be assured of the sensitivity and specificity of the assay. Evidence shows that there is 
much room for improvement in accuracy, with up to 20% false-negative results for ER/PgR, more than 12% false-positive results for PgR, 
and up to 15% false-positive results for HER2 [2].
Are there clinically important TNBC subtypes?
Audience voting
Most participants would not request additional tumour analyses (e.g. epidermal growth factor receptor (EGFR), cytokeratin 5/6, 14 and 17). 
The audience was divided almost equally over the issue of histological subtyping for patients who have been classified as having TNBC.
Expert opinion of Professor Giuseppe Viale
Patients with TNBC have some typical features, as shown in Table 1 [3,4], but there is a great heterogeneity in the underlying pathological 
tumour type (Table 2). The vast majority of tumours (70–85% [5,6]) are invasive ductal carcinomas not otherwise specified, but there are 
many other TNBC tumour subtypes and prognosis varies greatly. The answer to the question “Are you interested in subtyping TNBC?” 
should be “yes!”
Around 80% of TNBC has a basal-like gene expression [7]. Basal-like breast cancer is defined by expression of around 500 different mes-
senger RNA molecules. At the messenger RNA level, such tumours have a relatively high expression of a number of markers, including 
cytokeratin 5 and 17, EGFR, KIT, laminin, collagen type XVII, calponin 1 and calveolin 2, and a relatively low expression of ER or HER2. 
Currently, assessment of these markers has no impact on clinical treatment decisions, although the potential prognostic implications of 
surrogate markers is being investigated.
When confronted with an apparently triple-negative tumour, pathologists should follow a hierarchical approach to assessment, focus-
ing first on morphology to identify the subtypes with a good prognosis (i.e. adenoid-cystic, medullary, metaplastic low-grade, apocrine 
Clinical Younger patients (47–55 years)
African-American women
Interval cancers
BRCA1 mutations
Pathological features High grade, high mitotic count
Pushing borders (recalls medullary cancer of breast)
Geographic necrosis, central fibrosis
Stromal lymphocytic infiltrate
Metaplasia
Prevalence of brain and lung metastases even if the patient has negative lymph nodes
Table 1: Typical clinical and pathological features of triple-negative breast cancer (ref. [3,4]).ecancer 2011, 5:217
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low-grade). They should then confirm that the immunophenotype is truly nonendocrine-responsive (with <1% ER/PgR immunoreactive 
cells, and no false-negative results) and reassess equivocal IHC results. Further phenotyping could be performed for investigational 
purposes.
In summary, the definition of TNBC needs to be standardized and agreed by the international community. Clinicians need to understand 
the differences between TNBC and basal-like breast cancer and the importance of using a hierarchical approach to diagnosis, focusing 
on thorough evaluation of morphological features, followed by accurate assessment of receptor status (ER, PgR and HER2), with use of 
surrogate IHC markers or gene expression profiling assays to identify basal-like carcinomas if deemed appropriate.
Should patients be given adjuvant or neoadjuvant chemotherapy for TNBC?
Audience voting
Given a choice of potential treatments for Carole, the patient in this case study, 40% of the audience opted for neoadjuvant chemotherapy 
alone and 38% would consider additional adjuvant chemotherapy depending on pathological response to neoadjuvant treatment. The 
most popular selection of neoadjuvant chemotherapy was a sequential regimen of anthracycline followed by taxane (48%) or combination 
of these agents (38%). Around 13% of participants would consider neoadjuvant platinum-based treatment.
Tumour description Prognosis
Invasive ductal carcinoma not otherwise specified, high grade Poor
Invasive lobular carcinoma, pleomorphic type, high grade Poor
Metaplastic or myeloblastic carcinoma, high grade Poor
High-grade oat-cell neuroendocrine tumours Poor
Apocrine breast cancers (some may be HER2+) Depends on grade:
  Grade 1 = good
  Grade 2 = intermediate
  Grade 3 = poor
Medullary Good
Adenoid-cystic Good
Metaplastic low-grade (low-grade adenosquamous, fibromatosis like) Good
Table 2: Heterogeneity of tumour pathology and prognosis in triple-negative breast cancer.
Case study
In January 2010, the patient was started on a dose-dense epirubicin + cyclophosphamide regimen followed by weekly paclitaxel 
80 mg/m2. After four cycles of the anthracycline treatment, there was evidence of a slight decrease in tumour size but lymph nodes 
were still palpable. After 12 weeks of paclitaxel, the patient had clinical and radiological improvement (no lymph nodes, no meas-
urable disease). After tumorectomy and axillary lymph-node dissection in June 2010, the patient had no residual tumour and no 
lymph-node involvement (pT0N0).www.ecancermedicalscience.com 5
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Expert opinion of Professor Paul Ellis
Using pathological complete response (pCR) as a surrogate endpoint, there is evidence that TNBC is a chemo-responsive disease, 
with pCR rates of 20–45% after anthracycline or anthracycline/taxane-based treatments [8–11]. These rates are similar to those 
achieved in women with HER2+ disease, and substantially better than in endocrine-responsive disease. However, as Figure 1 shows, 
although patients with TNBC who achieve a pCR have a good prognosis, those without a pCR have a poor outcome, with a higher risk 
of relapse [10].
Neoadjuvant therapy may not have a role in all patients (e.g. those with small tumours that can be treated with surgery and standard 
adjuvant chemotherapy) but its use in many patients makes sense—in particular those in whom breast conservation is not possible or 
who have clinically involved nodes. In clinical trials, neoadjuvant therapy helps to address questions about treatment choices—an exam-
ple would be the use of different chemotherapy backbones to support novel therapeutic approaches such as inhibitors of poly-(ADP)
ribose polymerase (PARP)—and to use translational research to identify subgroups of TNBC patients who might benefit from different 
treatments.
Anthracyclines are commonly used in TNBC, and there is clinical trial evidence of a survival benefit versus no treatment (hazard ratios 
ranging from 0.35 (95% confidence interval 0.18–0.68) for nonbasal subtypes to 0.54 (0.27–1.08) for basal subtypes [12].) Furthermore, 
compared with cyclophosphamide + methotrexate + 5-fluorouracil, patients with TNBC achieved a superior benefit from anthracy-
clines [13], although the MA5 study [14] found the opposite result in a relatively small group of patients receiving cyclophosphamide + 
methotrexate + 5-fluorouracil or cyclophosphamide + epirubicin + 5-fluorouracil.
A meta-analysis of randomized trials has shown docetaxel to be as effective in TNBC as in non-TNBC patients in terms of disease-free 
survival (Figure 2) [15]: the hazard ratios for docetaxel versus no docetaxel were 0.67 (95% confidence interval 0.50–0.90) in 2,296 
Figure 1: Survival by tumour type and response status (adapted from ref. [10]). pCR, pathological complete response; TNBC, triple-negative 
breast cancer; RD, residual disease.ecancer 2011, 5:217
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TNBC patients (five studies) and 0.73 (0.61–0.88) in 2,089 non-TNBC patients (three studies). A similar benefit has been confirmed for 
paclitaxel [16]. Therefore, it seems reasonable that full-dose anthracycline/taxane-based therapy should be the standard of care for TNBC 
patients.
Data for platinum agents are less mature, although a number of studies in the neoadjuvant setting suggest a benefit in terms of pCR rates, 
particularly in patients with BRCA mutations (72% pCR with cisplatin [17]). However, in less selected TNBC patients, the pCR rates are 
only around 15–30% with cisplatin [18,19] and 22–40% with carboplatin [19–22]. A number of questions about platinum agents remain to 
be answered, such as the choice of agent and the relative benefit versus nonplatinum chemotherapies. For the time being, although they 
show promise, they should not yet be considered the standard of care in the neoadjuvant or adjuvant setting.
The potential impact of targeted therapies is being explored in TNBC. Evidence suggests that the addition of bevacizumab to an anthra-
cycline/taxane combination may be beneficial in ER-negative patients, although there is no benefit in the whole breast cancer population 
[23]. The addition of bevacizumab to chemotherapy is also being explored in the BEATRICE study [24]. A range of PARP inhibitor studies, 
being developed by different cooperative groups, could provide information on ways to optimize chemotherapy in the neoadjuvant treat-
ment of TNBC.
In summary, the evidence supports anthracycline/taxane combination therapy for early TNBC. The patient should receive a full course 
of treatment, whether in the neoadjuvant or the adjuvant setting. If she has received the full course before surgery, there is no need for 
further adjuvant chemotherapy outside a clinical trial. Our challenge is to help those patients who we know will do badly if they do not 
achieve a pCR, ideally exploring the use of new therapies with minimal use of cytotoxic agents.
Should patients and their families have genetic tests?
Figure 2: Disease-free survival with docetaxel by breast cancer subtype (adapted from ref. [15])
Case study
The familial history should be assessed in all young women with breast cancer. In this case study, Carole’s mother was diagnosed 
with hormone-sensitive breast cancer at the age of 56 years but there is no other confirmed case in the maternal family.www.ecancermedicalscience.com 7
ecancer 2011, 5:217
C
o
n
f
e
r
e
n
c
e
 
R
e
p
o
r
t
Audience voting
Two thirds of the audience would look for a genetic mutation (specifically BRCA1 and possibly BRCA2) in this patient. Assuming a genetic 
mutation was found, around a quarter of participants would screen the patient’s sisters as well, although very few would screen further 
family members.
Expert opinion of Professor Marc Abramowicz
Only a small minority of breast cancers are due to a hereditary mutation in a single gene (perhaps 5% [25]). Inherited mutations usually 
involve the BRCA1 or BRCA2 gene. Some families, however, have other mutations, which may not always be easy to identify with existing 
techniques.
When deciding whether to test a woman for a hereditary mutation, it must be borne in mind that other members of the family will be 
affected too, although it may not be feasible to test everyone at first. Furthermore, the result of the test does not guarantee that breast 
cancer will or will not develop. A sister without the mutation may still have breast cancer by chance, whereas many women with muta-
tions do not develop the disease [26]. Nonetheless, women can be assigned to risk categories to determine appropriate risk-reducing and 
management strategies.
Only a minority of TNBC patients are BRCA1 carriers, even in conspicuous familial cases when both the mother and daughter had onset 
in their early 30s [27]. As a result, it would be inappropriate to assess all TNBC patients for BRCA1 mutations: such testing would be 
labour-intensive and expensive, and would result in too many false-negatives and false-positives (i.e. genetic variants that do not result 
in disease), with associated mistaken reassurances or psychological impact on family members. Therefore, ASCO recommends that 
genetic testing should be performed in selected patients with personal or family history features suggesting a genetic cancer susceptibility 
(Table 3), with appropriate genetic counselling [28]. The test needs to be adequately interpreted and must be able to provide results that 
can guide diagnosis or treatment decisions for the patient or family members.
For Carole, in this case study, her father’s family history should be reviewed too, as men can also transmit mutations. As she had TNBC 
before the age of 50 years, she should be considered for BRCA1 testing. If she is found to have a BRCA1 mutation, her sisters should be 
offered testing, as should her daughter when she is an adult (i.e. around 20 years old). Her mother should also be tested, even though she 
has a history of ER-positive disease.
How should recurring or metastatic TNBC be treated?
Features suggestive of hereditary cancer among first-degree relatives (second-degree if paternal)
•  Two women with breast cancer diagnosed before the age of 50 years
•    One woman with breast cancer diagnosed before 50 years + one woman with ovarian cancer at any age or + one woman with bilateral breast 
cancer at any age
•  Four women with breast cancer only
•  One woman with breast + ovarian cancer
•  One woman with breast cancer diagnosed before the age of 30 years
•  One woman with triple-negative breast cancer diagnosed before 50 years
Offer genetic counselling before testing
Test affected family members first (i.e. those with history of breast cancer)
Table 3: Personal or familial features suggestive of hereditary cancer, as a guide for genetic testing (adapted from ASCO 2003 [26]).ecancer 2011, 5:217
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Audience voting
More than half of the audience suggested entering her into a clinical trial of a PARP inhibitor. Other options included platinum-based or 
taxane-based (docetaxel + capecitabine or gemcitabine; paclitaxel + bevacizumab) chemotherapy.
Expert opinion of Professor Lisa Carey
The heterogeneity described earlier for TNBC continues to manifest when the disease progresses to the metastatic stage. Slowly pro-
gressive or asymptomatic patients with small metastases present a different challenge from those with rapidly progressive, symptomatic 
disease, although in all cases the disease is not curable.
In asymptomatic patients, the goals of treatment are to control disease (i.e. to stop the tumour from growing, rather than trying to reduce 
tumour size) without exposing the patient to undue toxicity. In such patients, sequential single agents are the norm (if there is no appro-
priate clinical trial), and the choice depends on patient convenience, comorbidities and previous toxicities (95% of patients have already 
received neoadjuvant or adjuvant chemotherapy [29]). Possible treatments include taxanes, anthracyclines (e.g. liposomal doxorubicin), 
capecitabine, platinum agents, other microtubule-directed agents, vinorelbine and gemcitabine.
In patients with rapidly progressive and symptomatic metastatic disease, there is little need to balance efficacy and tolerability of treat-
ments, because the disease is likely to cause more toxicity than therapy would. The goal of treatment is to achieve a tumour response, 
and combination regimens always have higher response rates than single agents. Options include combinations involving bevacizumab, 
docetaxel + capecitabine, paclitaxel + gemcitabine, and ixabepilone + capecitabine.
As with the neoadjuvant and adjuvant settings, the jury is still out on the benefit of platinum-based treatments in the metastatic setting. 
Cisplatin monotherapy achieved only a 10% response rate in largely treatment-naive patients [30]. Carboplatin monotherapy achieved a 
17% response rate in patients who were largely pretreated with an EGFR inhibitor [31]. Until the results of further clinical trials are avail-
able, platinum-based treatment should probably not be a standard of care, although it could be considered in later lines of treatment for 
metastatic TNBC.
Novel anticancer agents such as PARP inhibitors and iniparib are eliciting a great deal of interest currently, although none is yet avail-
able outside clinical trials. Most data are available for iniparib, which is provoking most excitement in the setting of sporadic (i.e. not 
BRCA1-associated) TNBC. Iniparib does not possess characteristics typical of the PARP inhibitor class and investigations are currently 
in progress to elucidate its main mechanism of action. The recently published phase II study demonstrated that the addition of iniparib 
to gemcitabine + carboplatin improved the clinical benefit and survival of patients with metastatic TNBC, compared with chemotherapy 
alone, without significantly increased toxic effects (Figure 3) [32]. However, in the pivotal phase III trial, iniparib demonstrated activity 
but did not meet the statistically rigorous primary endpoint [33], although it is possible that subsets within the larger trial will demonstrate 
benefit; those analyses are ongoing.
Questions that remain to be answered include: Is DNA damage stimulus needed in non-BRCA+ tumours? Might PARP inhibitors and 
iniparib work in any breast cancer or will the benefit be seen only in TNBC patients? What secondary effects might occur with prolonged 
prevention of DNA damage repair?
Case study
Despite having achieved a pCR in June, Carole experienced a rapid cutaneous relapse and neuropathic pain. On clinical examina-
tion in October 2010, she was found to have skin infiltration and a right axillary mass. Imaging showed right diffuse carcinomatous 
mastitis, and there was evidence of axillary and retroperitoneal para-aortic lymph-node involvement.www.ecancermedicalscience.com 9
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Conclusions
In the opinions of this expert panel, three factors are critical when considering a patient with TNBC and deciding how best to manage her 
disease:
•  The quality of the initial pathology
•  The possibility of a genetic mutation, and the impact on the wider family
•  The challenges posed by the heterogeneity of the disease and the range of treatment options available
Breast cancer mortality is decreasing [34], but most benefits are seen in patients with ER-positive or HER2-positive disease. The only 
way that treatment for TNBC can improve is through clinical trials of new agents and new strategies. Therefore all patients should be 
encouraged to participate in clinical trials.
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